Cannabidiol lowers incidence of diabetes in non-obese diabetic mice

References

• Mbvundula EC, Rainsford KD, Bunning RA. Cannabinoids in pain and inflammation. Inflammopharmacology 2004; 12: 99–114
   PubMedGoogle Scholar
• Klein TW, Newton C, Friedman H. Cannabinoid receptors and immunity. Immunol Today 1998; 19: 373–381
   PubMedGoogle Scholar
• Howlett AC. The cannabinoid receptors. Prostaglandins Other Lipid Mediat 2002; 68-69: 619–631
   PubMed Web of Science ®Google Scholar
• Newton CA, Klein TW, Friedman H. Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection. Infect Immun 1994; 62: 4015–4020
   PubMed Web of Science ®Google Scholar
• Klein TW, Newton CA, Nakachi N, Friedman H. Delta 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-γ, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection. J Immunol 2000; 164: 6461–6466
   PubMed Web of Science ®Google Scholar
• Zhu LX, Sharma S, Stolina M, et al. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol 2000; 165: 373–380
   PubMed Web of Science ®Google Scholar
• Yuan M, Kiertscher SM, Cheng Q, Zoumalan R, Tashkin DP, Roth MD. Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T-cells. J Neuroimmunol 2002; 133: 124–131
   PubMed Web of Science ®Google Scholar
• Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61–65
   PubMed Web of Science ®Google Scholar
• Thomas BF, Gilliam AF, Burch DF, Roche MJ, Seltzman HH. Comparative receptor binding analyses of cannabinoid agonists and antagonists. J Pharmacol Exp Ther 1998; 285: 285–292
   PubMedGoogle Scholar
• Cunha JM, Carlini EA, Pereira AE, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980; 21: 175–185
   PubMed Web of Science ®Google Scholar
• Consroe P, Laguna J, Allender J, et al. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav 1991; 40: 701–708
   PubMed Web of Science ®Google Scholar
• Watzl B, Scuderi P, Watson RR. Influence of marijuana components (THC and CBD) on human mononuclear cell cytokine secretion in vitro. Adv Exp Med Biol 1991; 288: 63–70
   PubMedGoogle Scholar
• Malfait AM, Gallily R, Sumariwalla PF, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 2000; 97: 9561–9566
   PubMed Web of Science ®Google Scholar
• Costa B, Colleoni M, Conti S, et al. Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn Schmiedebergs Arch Pharmacol 2004; 369: 294–299
   PubMed Web of Science ®Google Scholar
• Gaoni Y, Mechoulam R. The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. J Am Chem Soc 1971; 93: 217–224
   PubMed Web of Science ®Google Scholar
• Ji YH, Weiss L, Zeira M, et al. Allogeneic cell-mediated immunotherapy of leukemia with immune donor lymphocytes to upregulate antitumor effects and downregulate antihost responses. Bone Marrow Transplant 2003; 32: 495–504
   PubMedGoogle Scholar
• Kikutani H, Makino S. The murine autoimmune diabetes model: NOD and related strains. Adv Immunol 1992; 51: 285–322
   PubMed Web of Science ®Google Scholar
• Wicker LS, Todd JA, Peterson LB. Genetic control of autoimmune diabetes in the NOD mouse. Annu Rev Immunol 1995; 13: 179–200
   PubMed Web of Science ®Google Scholar
• Pozzilli P, Signore A, Williams AJ, Beales PE. NOD mouse colonies around the world-recent facts and figures. Immunol Today 1993; 14: 193–196
   PubMedGoogle Scholar
• Yaacob NS, Kaderi MA, Norazmi MN. The expression of cytokine genes in the peritoneal macrophages and splenic CD4- and CD8-positive lymphocytes of the nonobese diabetic mice. J Clin Immunol 2004; 24: 177–184
   PubMedGoogle Scholar
• Rabinovitch A, Suarez-Pinzon WL, Sorensen O, Bleackley RC, Power RF. IFN-γ gene expression in pancreatic islet-infiltrating mononuclear cells correlates with autoimmune diabetes in nonobese diabetic mice. J Immunol 1995; 154: 4874–4882
   PubMed Web of Science ®Google Scholar
• Almawi WY, Tamim H, Azar ST. Clinical review 103: T helper type 1 and 2 cytokines mediate the onset and progression of type I (insulin-dependent) diabetes. J Clin Endocrinol Metab 1999; 84: 1497–1502
   PubMed Web of Science ®Google Scholar
• Satoh J, Takahashi K, Nakazawa T, Sakata Y, Toyota T. [Current concept of the pathogenesis of autoimmune type 1 diabetes mellitus. Nippon Rinsho 1999; 57: 528–533
   PubMedGoogle Scholar
• Chang JC, Linarelli LG, Laxer JA, et al. Insulin-secretory-granule specific Tcell clones in human IDDM. J Autoimmun 1995; 8: 221–234
   PubMedGoogle Scholar
• Gallichan WS, Balasa B, Davies JD, Sarvetnick N. Pancreatic IL-4 expression results in islet-reactive Th2 cells that inhibit diabetogenic lymphocytes in the nonobese diabetic mouse. J Immunol 1999; 163: 1696–1703
   PubMed Web of Science ®Google Scholar
• Healey D, Ozegbe P, Arden S, Chandler P, Hutton J, Cooke A. In vivo activity and in vitro specificity of CD4+Th1 and Th2 cells derived from the spleens of diabetic NOD mice. J Clin Invest 1995; 95: 2979–2985
   PubMed Web of Science ®Google Scholar
• Bach JF, Boitard C. Experimental models of type-I diabetes. Pathol Immunopathol Res 1986; 5: 384–415
   PubMedGoogle Scholar
• Bach JF. The Non Obese Diabetic (NOD) mouse, as a model of Tcell mediated autoimmune disease. C R Acad Sci III 1992; 314: 45–46
   PubMedGoogle Scholar
• Greiner DL, Rossini AA, Mordes JP. Translating data from animal models into methods for preventing human autoimmune diabetes mellitus: Caveat emptor and primum non nocere. Clin Immunol 2001; 100: 134–143
   PubMedGoogle Scholar
• Stiller CR, Dupre J, Gent M, et al. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 1984; 223: 1362–1367
   PubMed Web of Science ®Google Scholar
• Bougneres PF, Landais P, Boisson C, et al. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes 1990; 39: 1264–1272
   PubMed Web of Science ®Google Scholar
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977–986
   PubMed Web of Science ®Google Scholar
• Swain SL. T-cell subsets. Who does the polarizing?. Curr Biol 1995; 5: 849–851
   PubMedGoogle Scholar
• Jun HS, Santamaria P, Lim HW, Zhang ML, Yoon JW. Absolute requirement of macrophages for the development and activation of beta-cell cytotoxic CD8+T-cells in T-cell receptor transgenic NOD mice. Diabetes 1999; 48: 34–42
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133–146
   PubMed Web of Science ®Google Scholar
• Skeen MJ, Miller MA, Shinnick TM, Ziegler HK. Regulation of murine macrophage IL-12 production. Activation of macrophages in vivo, restimulation in vitro, and modulation by other cytokines. J Immunol 1996; 156: 1196–1206
   PubMed Web of Science ®Google Scholar
• Ohno Y, Aoki N, Nishimura A. In vitro production of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1993; 77: 1072–1077
   PubMed Web of Science ®Google Scholar
• Abdel Aziz MT, Fouad HH, Mohsen GA, Mansour M, Abdel Ghaffar S. TNF-α and homocysteine levels in type 1 diabetes mellitus. East Mediterr Health J 2001; 7: 679–688
   PubMedGoogle Scholar
• Hunger RE, Carnaud C, Garcia I, Vassalli P, Mueller C. Prevention of autoimmune diabetes mellitus in NOD mice by transgenic expression of soluble tumor necrosis factor receptor p55. Eur J Immunol 1997; 27: 255–261
   PubMedGoogle Scholar
• Rabinovitch A, Suarez-Pinzon WL. Cytokines and their roles in pancreatic islet beta-cell destruction and insulin-dependent diabetes mellitus. Biochem Pharmacol 1998; 55: 1139–1149
   PubMed Web of Science ®Google Scholar
• Adorini L, Trembleau S. Immune deviation towards Th2 inhibits Th-1-mediated autoimmune diabetes. Biochem Soc Trans 1997; 25: 625–629
   PubMed Web of Science ®Google Scholar
• Liblau RS, Singer SM, McDevitt HO. Th1 and Th2 CD4+Tcells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995; 16: 34–38
   PubMedGoogle Scholar
• Rapoport MJ, Jaramillo A, Zipris D, et al. Interleukin 4 reverses T-cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 1993; 178: 87–99
   PubMed Web of Science ®Google Scholar
• Cameron MJ, Arreaza GA, Zucker P, et al. IL-4 prevents insulitis and insulin-dependent diabetes mellitus in nonobese diabetic mice by potentiation of regulatory T helper-2 cell function. J Immunol 1997; 159: 4686–4692
   PubMed Web of Science ®Google Scholar
• Tominaga Y, Nagata M, Yasuda H, et al. Administration of IL-4 prevents autoimmune diabetes but enhances pancreatic insulitis in NOD mice. Clin Immunol Immunopathol 1998; 86: 209–218
   PubMed Web of Science ®Google Scholar
• Mueller R, Krahl T, Sarvetnick N. Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 1996; 184: 1093–1099
   PubMed Web of Science ®Google Scholar
• Rabinovitch A, Suarez-Pinzon WL, Sorensen O, Bleackley RC, Power RF, Rajotte RV. Combined therapy with interleukin-4 and interleukin-10 inhibits autoimmune diabetes recurrence in syngeneic islet-transplanted nonobese diabetic mice. Analysis of cytokine mRNA expression in the graft. Transplantation 1995; 60: 368–374
   PubMedGoogle Scholar
• Kolb H. Benign versus destructive insulitis. Diabetes Metab Rev 1997; 13: 139–146
   PubMedGoogle Scholar
• Kaufman DL, Clare-Salzler M, Tian J, et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993; 366: 69–72
   PubMed Web of Science ®Google Scholar
• Tian J, Chau C, Kaufman DL. Insulin selectively primes Th2 responses and induces regulatory tolerance to insulin in pre-diabetic mice. Diabetologia 1998; 41: 237–240
   PubMedGoogle Scholar